Immediate Impact
2 from Science/Nature 55 standout
Citing Papers
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Fluorescent Probes for Disease Diagnosis
2024 Standout
Works of Α. Kotsakis being referenced
3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Α. Kotsakis | 220 | 144 | 130 | 23 | 332 | |
| Francesca Sparano | 206 | 98 | 107 | 19 | 339 | |
| Yu Zhang | 208 | 93 | 108 | 23 | 371 | |
| T Toge | 141 | 113 | 113 | 29 | 321 | |
| Hsiang‐Fong Kao | 205 | 105 | 122 | 26 | 362 | |
| Eduardo Caetano Albino da Silva | 119 | 116 | 137 | 28 | 336 | |
| Marisol Miranda Galvis | 131 | 47 | 83 | 25 | 285 | |
| Norihiro Matsuura | 167 | 50 | 106 | 26 | 337 | |
| Xinhua Xu | 119 | 44 | 189 | 20 | 304 | |
| Lydia Koi | 140 | 106 | 152 | 19 | 363 | |
| Feiteng Lu | 97 | 55 | 108 | 21 | 280 |
All Works
Loading papers...